VITRO BIOPHARMA, INC.: 10-Q filed 2012-03-21
What VITRO BIOPHARMA, INC. reported in its quarterly report filed 2012-03-21 (fiscal Q1 2012): 28 published measures, 58 facts as tagged in accession 0001376474-12-000066.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-03-21
- Fiscal period
- fiscal Q1 2012
- Accession
- 0001376474-12-000066 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VITRO BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 81,164 | USD | |
| At 2011-10-31 | 86,374 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 2,975 | USD | |
| At 2011-10-31 | 3,023 | USD | |
| At 2010-10-31 | 17,313 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | -62,426 | USD | 92 |
| 2010-11-01 to 2011-01-31 | -40,107 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | -55,699 | USD | 92 |
| 2010-11-01 to 2011-01-31 | -54,569 | USD | 92 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 56,946 | USD | 92 |
| 2010-11-01 to 2011-01-31 | 53,413 | USD | 92 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | -1,295 | USD | 92 |
| 2010-11-01 to 2011-01-31 | -4,728 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | -6,989,862 | USD | |
| At 2011-10-31 | -6,927,436 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 18,528,995 | shares | 92 |
| 2010-11-01 to 2011-01-31 | 18,379,985 | shares | 92 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 18,528,995 | shares | 92 |
| 2010-11-01 to 2011-01-31 | 18,379,985 | shares | 92 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 0 | USD/shares | 92 |
| 2010-11-01 to 2011-01-31 | 0 | USD/shares | 92 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 0 | USD/shares | 92 |
| 2010-11-01 to 2011-01-31 | 0 | USD/shares | 92 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 28,692 | USD | |
| At 2011-10-31 | 31,819 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 3,125 | USD | 92 |
| 2010-11-01 to 2011-01-31 | 3,559 | USD | 92 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | -51,820 | USD | 92 |
| 2010-11-01 to 2011-01-31 | -58,799 | USD | 92 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 22,492 | USD | |
| At 2011-10-31 | 23,790 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | -10,606 | USD | 92 |
| 2010-11-01 to 2011-01-31 | -10,608 | USD | 92 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 1,701,926 | USD | |
| At 2011-10-31 | 1,652,635 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 22,936 | USD | |
| At 2011-10-31 | 23,721 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 18,867 | USD | |
| At 2011-10-31 | 17,173 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 1,978 | USD | 92 |
| 2010-11-01 to 2011-01-31 | 3,088 | USD | 92 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 24,214 | USD | 92 |
| 2010-11-01 to 2011-01-31 | 19,705 | USD | 92 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 29,584 | USD | 92 |
| 2010-11-01 to 2011-01-31 | 42,182 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 18,871,217 | shares | |
| At 2011-10-31 | 18,528,995 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 5,361,062 | USD | |
| At 2011-10-31 | 5,346,604 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | -1,620,762 | USD | |
| At 2011-10-31 | -1,566,261 | USD | |
| At 2010-10-31 | -1,585,740 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-01-31 | 10,513 | USD | |
| At 2011-10-31 | 2,903 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | -62,426 | USD | 92 |
| 2010-11-01 to 2011-01-31 | -40,107 | USD | 92 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-01-31 | 5,207 | USD | 92 |
| 2010-11-01 to 2011-01-31 | 5,082 | USD | 92 |
Inspect the source
- Entity
- VITRO BIOPHARMA, INC. / CIK 0000793171
- Captured
- 2026-09-21T17:17:03.076Z
- SEC response SHA-256
e4a45888e3fd56bf245fee78b2235f6f8d9c94b7a357b46c64ff1e0e8b6cac32
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000793171.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))